Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the safety and effectiveness of tabirafusp tedromer compared to aflibercept in people with diabetic macular edema DME, a condition causing vision impairment related to diabetes. This phase 3 randomized trial aims to evaluate these two treatments administered by injection into the eye, focusing on improving vision clarity. Participants receive intravitreal injections of either tabirafusp tedromer or aflibercept. Tabirafusp tedromer is given once every 4 weeks for six doses, then either every 8 weeks or individualized between every 4 to 24 weeks depending on the group. Aflibercept is administered every 4 weeks for five doses, followed by every 8 weeks. The study compares these dosing schedules over time to assess treatment impact. During the trial, participants undergo regular eye exams to measure best corrected visual acuity at week 52 and other safety assessments. The study includes monitoring of treatment effects and side effects through scheduled visits with injections and vision tests. Participation lasts through the treatment and evaluation period, allowing researchers to gather data on vision changes and overall safety.